替雷利珠单抗结合常规化疗药物在晚期非小细胞肺癌患者中的临床疗效及对血清肿瘤标志物的影响

Clinical efficacy of tislelizumab combined with conventional chemotherapeutic agents in patients with advanced non-small cell lung cancer and its influence on serum tumor markers

目的探讨替雷利珠单抗联合常规化疗药物治疗晚期非小细胞肺癌患者的临床疗效及对血清肿瘤标志物水平的影响。方法回顾性选择晚期非小细胞肺癌患者80例,其中40例行吉西他滨单药治疗的患者为对照组,40例行吉西他滨联合替雷利珠单抗治疗的患者为观察组。观察并比较两组患者临床疗效,治疗前后血清肿瘤标志物[糖类抗原125(CA125)、癌胚胎抗原(CEA)、神经元特异性烯醇化酶(NSE)]水平,治疗前后健康调查简表(SF-36)评分及药物不良反应发生情况。结果与对照组(70.0%)比较,观察组患者的疾病缓解率(90.0%)明显更高(P<0.05)。与治疗前比较,两组患者治疗3个疗程后SF-36评分均有明显改善(P<0.05);且与对照组的(63.28±4.63)分比较,观察组患者治疗3个疗程后的SF-36评分(86.34±5.32)分明显更高(P<0.05)。治疗前,两组患者血清CA125、CEA、NSE水平比较无差异(P>0.05);与治疗前比较,两组患者治疗3个疗程后血清CA125、CEA和NSE水平均有所降低(P<0.05);治疗3个疗程后观察组患者血清CA125、CEA和NSE水平分别为(32.92±2.38)U/ml、(16.85±2.23)ng/ml、(6.54±1.67)ng/ml,明显低于对照组的(63.32±2.31)U/ml、(29.27±2.29)ng/ml、(22.15±1.88)ng/ml(P<0.05)。观察组患者药物不良反应发生率(5.0%)与对照组(7.5%)比较无差异(P>0.05)。结论晚期非小细胞肺癌患者经替雷利珠单抗与常规化疗药物联合治疗后,患者的临床症状明显得到改善,临床疗效显著升高,能有效降低血清中肿瘤标志物水平,提高患者的生活质量水平,且安全性良好,值得临床推广使用。

Objective To explore the clinical efficacy of tislelizumab combined with conventional chemotherapeutic agents in patients with advanced non-small cell lung cancer and its influence on serum tumor markers.Methods 80 patients with advanced non-small cell lung cancer were retrospectively selected,of which 40 patients receiving gemcitabine monotherapy were included as the control group and 40 patients receiving gemcitabine combined with tislelizumab as the observation group.Observation and comparison were made on clinical efficacy,serum tumor markers[carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),neuron-specific enolase(NSE)]levels,36-item short-form health survey(SF-36)score before and after treatment,and incidence of adverse drug reactions between the two groups.Results Compared with the control group(70.0%),the disease remission rate of the observation group(90.0%)was significantly higher(P<0.05).Compared with before treatment,SF-36 scores in both groups were significantly improved after 3 courses of treatment(P<0.05).Compared with the control group[(63.28±4.63)points],SF-36 score of the observation group[(86.34±5.32)points]was significantly higher(P<0.05).Before treatment,there were no differences in serum CA125,CEA and NSE levels between the two groups(P>0.05).Compared with before treatment,the serum CA125,CEA and NSE levels in both groups were decreased after 3 courses of treatment(P<0.05).After 3 courses of treatment,the serum levels of CA125,CEA and NSE in the observation group were(32.92±2.38)U/ml,(16.85±2.23)ng/ml and(6.54±1.67)ng/ml,which were significantly lower than(63.32±2.31)U/ml,(29.27±2.29)ng/ml and(22.15±1.88)ng/ml in the control group(P<0.05).There was no difference in the incidence of adverse drug reactions between the control group(7.5%)and the observation group(5.0%)(P>0.05).Conclusion After the combination treatment of tislelizumab and conventional chemotherapeutic agents,the clinical symptoms of patients with advanced non-small cell lung cancer are significantly improved,and the clinical efficacy is significantly enhanced.It can effectively reduce the serum levels of tumor markers,improve the quality of life of patients,and has good safety,which is worthy of clinical promotion.